Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian Cancer

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Jing-Yi Chern, MD, ScM, a gynecologic oncologist at Moffitt Cancer Center, discussesoutcomes with PARP inhibitors in patients with recurrent ovarian cancer. 

Two trials, the phase 3 ENGOT-OV16/NOVA (NCT01847274) and SOLO-2 (NCT01874353) trials, shed light on the use of these agents in patients with platinum-sensitive recurrent ovarian cancer, Chern says. These patients likely have not received treatment with PARP inhibition in the frontline setting. As such, the goal is to increase the platinum-free interval, because the impact of a long interval can improve overall outcomes, including survival, Chern explains.

Both studies show that PARP inhibition allows for that improvement, Chern notes. Additionally, patients whose tumors harbored a germline BRCA mutation who were included in the NOVA study experienced a median PFS pf 21.0 months with the PARP inhibitor niraparib (Zejula) vs 5.5 months with placebo, Chern concludes.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute